Director, Pre-clinical Pharmacology
KalVista Pharmaceuticals
Cambridge, Massachusetts, United States
Allen Clermont, MS - Biomedical Engineering. Director, Pre-clinical Pharmacology, KalVista Pharmaceuticals, Cambridge, MA, USA. I have 30+ years of research experience as junior faculty at Harvard Medical School involving basic, translational and clinical projects. I have been a co-investigator for NIH RO1
and S10 awards and the Massachusetts Lions Eye Research grants. I have managed the DRC funded Animal Physiology Core as its assistant director which provided contract studies for rodent metabolism and in vivo CT, bioluminescent and fluorescent imaging. My research has focused on the vascular complications of diabetes upon the retina. Utilizing commercial and custom designed optical imaging systems, I have investigated the function of retinal proteins and enzymes in the regulation of vascular blood flow, permeability, autoregulation, retinal neuronal responses and retinal tissue swelling. I have identified relevant functional endpoints in animal models that correlate into human retinal diseases for Phase I trials. My current research has focused on the role of the kallikrein-kinin system (KKS) in the development of diabetic retinopathy and macular edema using genetic mouse models and the investigation of potential therapeutics targeting this pathway. At KalVista, we design small molecular oral inhibitors to plasma kallikrein and factor XII for therapeutic and prophylactic intervention for hereditary angioedema.
PB0536 - Oral Factor XIIa inhibitor KV998086 protects against FeCl3 induced thrombosis in mice.
Monday, June 26, 2023
18:30 – 19:30 ET